The expression levels of HDAC3 and FOXA1 were significantly increased in ovarian cancer recurrence (HDAC3: p < 0.001, FOXA1: p = 0.002) and predicted adverse clinical outcomes in patients with ovarian cancer (HDAC3: p < 0.001, FOXA1: p < 0.001). Here, FOXA1 is linked to ovarian cancer.